Synthetic thyrotropin releasing factor as a test of pituitary thyrotropin reserve

Norman Fleischer, Maria Lorente, John Kirkland, Rebecca Kirkland, George Clayton, Marcos Calderon

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


The iv administration of 0.5 mg of synthetic thyroptropin releasing factor (TRF) to control subjects increased plasma TSH from baseline levels of 2.1 ± 0.01 µU/ml to peak values of from 8.5-27 µU/ml. Plasma TSH levels in subjects with primary myxedema were elevated and rose further following TRF. In seven of 16 euthyroid subjects with pituitary tumors, peak values of plasma TSH following TRF ranged from 2.5-6.5 µU/ml indicating limited reserve for TSH secretion. Subjects with hypothyroidism secondary to Sheehan’s syndrome or pituitary tumors did not alter their plasma TSH levels following TRF indicating inadequate pituitary function. Plasma TSH rose normally following TRF in five subjects with TSH deficiency in the absence of a known organic pituitary lesion. This latter group of subjects may have TRF deficiency as a cause of their decreased TSH secretion.

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Issue number4
StatePublished - Jan 1 1972

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Synthetic thyrotropin releasing factor as a test of pituitary thyrotropin reserve'. Together they form a unique fingerprint.

Cite this